Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

This study found cefiderocol was non-inferior to imipenem-cilastatin for the primary endpoint (composite of clinical and microbiological outcomes 7 days after treatment cessation; 73% vs 55%, respectively; adjusted treatment difference 18.58%, 95% CI 8.23-28.92; p=0.0004)
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news